Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 1 114 CHF 0.91% Market Closed
Market Cap: 4.8B CHF
Have any thoughts about
Siegfried Holding AG?
Write Note

Siegfried Holding AG
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Siegfried Holding AG
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Accounts Receivables
CHf355.2m
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Accounts Receivables
CHf136m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
15%
Lonza Group AG
SIX:LONN
Accounts Receivables
CHf1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Tecan Group AG
SIX:TECN
Accounts Receivables
CHf183m
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Accounts Receivables
€78.8m
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Accounts Receivables
CHf26.5m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Market Cap
4.8B CHF
Industry
Life Sciences Tools & Services

Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. The company is headquartered in Zofingen, Aargau and currently employs 3,432 full-time employees. The firm produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The firm's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The firm operates production facilities in Switzerland, Germany, France, Malta, the United States and China.

SFZN Intrinsic Value
1 192.72 CHF
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Siegfried Holding AG's Accounts Receivables?
Accounts Receivables
355.2m CHF

Based on the financial report for Jun 30, 2024, Siegfried Holding AG's Accounts Receivables amounts to 355.2m CHF.

What is Siegfried Holding AG's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
15%

Over the last year, the Accounts Receivables growth was 11%. The average annual Accounts Receivables growth rates for Siegfried Holding AG have been 17% over the past three years , 15% over the past five years .

Back to Top